Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00180284 · ClinicalTrials.gov registry record · Phase 3

SITELINE 2 Polyurethane

A Phase 3 study of Bradycardia, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
200
Enrollment target
1
Study location

NCT00180284: Completed Phase 3 study of Bradycardia, sponsored by Boston Scientific Corporation.

NCT00180284 is a Phase 3 study of Bradycardia that has completed, run by Boston Scientific Corporation. The registered enrollment target is 200 participants, below the 4,406-participant average among 29 other Bradycardia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00180284, a Phase 3 study of Bradycardia, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The SITELINE 2 Polyurethane Clinical Investigation analyzed the safety and electrical performance of the SITELINE 2 Polyurethane pacing lead.

Conditions Studied

Interventions

  • DEVICE SITELINE 2 Polyurethane (pacing lead)

Study Locations (1)

Minnesota

  • Multiple Locations in the United States - Saint Paul

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2004-11
Est. Completion 2008-02
Phase Phase 3
Boston Scientific Corporation

280 total trials

What the finished NCT00180284 record still lists

NCT00180284 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 4,406-participant average among 29 other Bradycardia trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which SITELINE 2 Polyurethane (pacing lead) is the first listed.

NCT00180284 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00180284 about?

NCT00180284 is a clinical study titled "SITELINE 2 Polyurethane". The SITELINE 2 Polyurethane Clinical Investigation analyzed the safety and electrical performance of the SITELINE 2 Polyurethane pacing lead.

What is the current status of trial NCT00180284?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2004-11. Estimated completion is 2008-02.

What conditions does trial NCT00180284 study?

This clinical trial studies the following conditions: Bradycardia.

What interventions are being tested in trial NCT00180284?

The interventions under investigation include: SITELINE 2 Polyurethane (pacing lead) (DEVICE).

Who is sponsoring clinical trial NCT00180284?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00180284 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bradycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00180284's enrollment target sits among peer trials

200 22nd of 29 higher than 8 of 29 other Bradycardia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00180284, the US trial registry maintained by the National Library of Medicine. NCT00180284 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.